Researchers report highest-resolution model to date of brain receptor behind marijuana's high
Researchers at UT Southwestern Medical Center report the most detailed 3-D structure to date of the brain receptor that binds and responds to the chemical at the root of marijuana's high.
Their high-resolution structure of the human cannabinoid receptor 1 (CB1) and its binding site for the chemical tetrahydrocannabinol (THC) should lead to a better understanding of how marijuana affects the brain. The research also could aid discovery of new treatments for conditions that target the receptor, said Dr. Daniel Rosenbaum, Assistant Professor of Biophysics and Biochemistry at UT Southwestern.
"What is most exciting from a therapeutic standpoint is that the same receptor pocket that binds THC also binds cannabinoid inhibitors that have been studied as possible treatments for conditions such as obesity," said Dr. Rosenbaum, senior author of the study published online today by Nature.
"The structure is an important step toward explaining how cannabinoids initiate signals in the brain that affect the release of neurotransmitters that relay messages between the brain's neurons," Dr. Rosenbaum said. "This 3-D structure provides high-resolution details of the binding pocket in the CB1 receptor, where plant cannabinoids like THC, cannabinoids made in the body, and synthetic cannabinoid inhibitors all work to modulate receptor function and physiology."
He said the CB1 receptor is the target for cannabinoid inhibitor drugs now under study as possible treatments for epilepsy, pain control, obesity, and other conditions.
In a competing study released last month by the journal Cell, a U.S.-Chinese team of researchers reported a 3-D structure of the CB1 receptor at a resolution of 2.8 angstroms. The UT Southwestern study reports a higher resolution of 2.6 angstroms. (One angstrom is equivalent to one hundred-millionth of a centimeter.) The higher the resolution, the finer the details of the relationship between atoms of the protein.
The Cell study examined the CB1 receptor bound to a synthetic chemical created to stabilize the receptor. In contrast, the UT Southwestern research team successfully imaged the receptor bound to the drug taranabant, which was tested as a possible anti-obesity treatment in clinical trials. Those trials ended due to side effects such as anxiety and depression, Dr. Rosenbaum said.
CB1 and the related CB2, which still lacks a high-resolution structural solution, are both members of the human G protein-coupled receptor family. Members of that receptor family control signaling pathways involving hormones, neurotransmitters, and sensory stimuli such as light and odors.
The team's success depended on overcoming the receptor protein's resistance to crystallization, which is required for the diffraction measurements used in X-ray crystallography. The researchers also conducted computer simulations of how THC might bind to the CB1 receptor, he said.
The next step is to obtain structures of CB1 actually bound to THC, he said.
Dr. Rosenbaum, a Eugene McDermott Scholar in Medical Research at UT Southwestern, was listed as one of the world's most highly cited researchers in 2014, according to data compiled by Thomson Reuters. This is his second study published in Nature in the past six months. His earlier study pertained to the structural biology of an important membrane protein involved in cholesterol metabolism.